Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Capital Leases: 2016-2018

Historic Capital Leases for ImmunityBio (IBRX) over the last 3 years, with Dec 2018 value amounting to $5.9 million.

  • ImmunityBio's Capital Leases rose 241.47% to $5.9 million in Q4 2018 from the same period last year, while for Dec 2018 it was $5.9 million, marking a year-over-year increase of 241.47%. This contributed to the annual value of $5.9 million for FY2018, which is 241.47% up from last year.
  • ImmunityBio's Capital Leases amounted to $5.9 million in FY2018, which was up 241.47% from $1.7 million recorded in FY2017.
  • In the past 5 years, ImmunityBio's Capital Leases ranged from a high of $5.9 million in FY2018 and a low of $1.7 million during FY2017.
  • Over the past 3 years, ImmunityBio's median Capital Leases value was $2.0 million (recorded in 2016), while the average stood at $3.2 million.
  • In the last 5 years, ImmunityBio's Capital Leases dropped by 14.02% in 2017 and then skyrocketed by 241.47% in 2018.
  • Over the past 3 years, ImmunityBio's Capital Leases (Yearly) stood at $2.0 million in 2016, then fell by 14.02% to $1.7 million in 2017, then spiked by 241.47% to $5.9 million in 2018.